{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:53:21Z","timestamp":1781661201586,"version":"3.54.5"},"reference-count":19,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>The use of long-acting lipoglycopeptides (LaLGPs) in serious, deep-seated infections is of increasing interest. The purpose of this study is to evaluate the economic and clinical utility of LaLGPs in patients requiring protracted antibiotic courses who are not ideal candidates for oral transition or outpatient parenteral antibiotic therapy (OPAT). This is a retrospective, observational, matched cohort study of adult patients who received a LaLGP. Patients were matched 1:1 to those who received standard of care (SOC). Cost effectiveness was evaluated as total healthcare-related costs between groups. Clinical failure was a composite endpoint of mortality, recurrence, or need for extended antibiotics beyond planned course within 90 days of initial infection. There was no difference in clinical failure between the two cohorts (22% vs. 30%; p = 0.491). Six patients in the SOC cohort left against medical advice (AMA) prior to completing therapy. Among those who did not leave AMA, receipt of LaLGPs resulted in a decreased hospital length of stay by an average of 13.6 days. The average total healthcare-related cost of care was USD 295,589 in the LaLGP cohort compared to USD 326,089 in the SOC cohort (p = 0.282). Receipt of LaLGPs may be a beneficial treatment option for patients with deep-seated infections and socioeconomic factors who are not candidates for oral transition or OPAT.<\/jats:p>","DOI":"10.3390\/pharmacy10010001","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T02:01:19Z","timestamp":1640224879000},"page":"1","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical Utility and Cost Effectiveness of Long-Acting Lipoglycopeptides Used in Deep-Seated Infections among Patients with Social and Economic Barriers to Care"],"prefix":"10.3390","volume":"10","author":[{"given":"Kayla","family":"Antosz","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC 29208, USA"},{"name":"Prisma Health Midlands, Columbia, SC 29203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6501-492X","authenticated-orcid":false,"given":"Majdi N.","family":"Al-Hasan","sequence":"additional","affiliation":[{"name":"Prisma Health Midlands, Columbia, SC 29203, USA"},{"name":"Department of Medicine, Division of Infectious Diseases, University of South Carolina School of Medicine, Columbia, SC 29209, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Kevin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC 29208, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Tabor","sequence":"additional","affiliation":[{"name":"Prisma Health Midlands, Columbia, SC 29203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4161-9577","authenticated-orcid":false,"given":"Julie Ann","family":"Justo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC 29208, USA"},{"name":"Prisma Health Midlands, Columbia, SC 29203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Milgrom","sequence":"additional","affiliation":[{"name":"Prisma Health Midlands, Columbia, SC 29203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kohn","sequence":"additional","affiliation":[{"name":"Prisma Health Midlands, Columbia, SC 29203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4409-0963","authenticated-orcid":false,"given":"P. Brandon","family":"Bookstaver","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia, SC 29208, USA"},{"name":"Prisma Health Midlands, Columbia, SC 29203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1742-1241.2007.01318.x","article-title":"Dalbavancin: A novel antimicrobial","volume":"61","author":"Chen","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"ref_2","unstructured":"(2021, September 08). Dosing. Available online: https:\/\/www.dalvance.com\/about-dalvance\/dosing-and-administration."},{"key":"ref_3","unstructured":"(2021, September 08). Dosing and Administration. Available online: http:\/\/www.orbactiv.com\/dosing-and-administration.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofy109","article-title":"Impact of outpatient vs inpatient ABSSSI treatment on outcomes: A retrospective observational analysis of medical charts across US emergency departments","volume":"5","author":"Bookstaver","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/cid\/ciy279","article-title":"Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2 year experience at the general hospital of Vienna","volume":"67","author":"Tobudic","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"ofz274","DOI":"10.1093\/ofid\/ofz274","article-title":"Long-acting lipoglycopeptides: \u201clineless antibiotics\u201d for serious infections in persons who use drugs","volume":"6","author":"Morrisette","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40121-020-00347-w","article-title":"Financial analysis of dalbavancin for acute bacterial skin and skin structure infections for self-pay patients","volume":"9","author":"Pizzuti","year":"2020","journal-title":"Infect. Dis. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/ejhpharm-2020-002315","article-title":"Effectiveness, safety and cost analysis of dalbavancin in clinical practice","volume":"29","year":"2022","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e1443","DOI":"10.1093\/cid\/ciaa1730","article-title":"Stewarding the costly antibiotic: Considerations for dalbavancin","volume":"73","author":"Milgrom","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"106107","DOI":"10.1016\/j.ijantimicag.2020.106107","article-title":"Current trends in the real-life use of dalbavancin: Report of a study panel","volume":"56","author":"Gambardella","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/phar.2389","article-title":"Advantages of outpatient treatment with long-acting lipoglycopeptides for serious gram-positive infections: A review","volume":"40","author":"Krsak","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"OVIVA Trial Collaborators. Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1808312","article-title":"Partial oral versus intravenous antibiotic treatment of endocarditis","volume":"380","author":"Iversen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/ofid\/ofw172.1036","article-title":"Risk factors associated with outpatient parenteral antibiotic therapy program failure among intravenous drug users","volume":"3","author":"Buehrle","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13756-016-0161-0","article-title":"Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: A prospective cohort study","volume":"6","author":"Grau","year":"2017","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_18","first-page":"e1579","article-title":"Small-town America\u2019s despair: Infected substance users needing outpatient parenteral therapy and risk stratification","volume":"9","author":"Camsari","year":"2017","journal-title":"Cureus"},{"key":"ref_19","unstructured":"(2021, September 08). Patient Assistance, Dalvance. Available online: https:\/\/www.abbvie.com\/patients\/patient-assistance\/program-qualification\/dalvance-program-selection.html#myabbvie."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/10\/1\/1\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:51:37Z","timestamp":1760169097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/10\/1\/1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["pharmacy10010001"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy10010001","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,23]]}}}